Print this page Email this page
Users Online: 90
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Contacts Login 
Year : 2017  |  Volume : 31  |  Issue : 1  |  Page : 8-13

Primary mediastinal large B cell lymphoma: Frontline treatment with an alternating chemotherapy regimen based on high dose methotrexate - A single institution experience

1 Department of Hematology, University Hospital Leipzig, Johannisallee 32A 04103, Germany
2 Department of Radiology, University Hospital Leipzig, Liebigstr 20 04103, Germany
3 Department of Radiotherapy, St. Georg Hospital, Delitzscher Str. 141 04129, Leipzig, Germany

Correspondence Address:
Wolfram Poenisch
Department of Hematology, University Hospital Leipzig, Johannisallee 32A 04103, Leipzig
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0972-4958.198427

Rights and Permissions

Background and Aims: In this retrospective analysis, we report our experience with the high-dose methotrexate-based chemotherapy B-ALL protocol of the German ALL study group followed by consolidative mediastinal radiotherapy in patients with adult primary mediastinal large B-cell lymphoma (PMLBCL) as a single-center trial. Setting and Design: Nineteen patients with newly diagnosed/untreated PMLBCL who were treated between June 1999 and May 2013 were included. Patients received a high-dose methotrexate protocol consisting of six cycles. Materials and Methods: Patients received thrice block A [day 1: methotrexate 1,500 mg/m2 for 24 h; days 1-5: ifosfamide 800 mg/m2; days 4-5: VM-26 100 mg/m2 and ara-C 2x150 mg/m2 (bid); days 1-5: dexamethasone 10 mg/m2 p.o.] and thrice block B [day 1: vincristine 2 mg i.v., MTX as in block A; days 1-5: cyclophosphamide 200 mg/m2; days 4-5: adriamycin 25 mg/m2; days 1-5: dexamethasone 10 mg/m2 p.o.] applied alternatively every 3 weeks. Results: After chemotherapy five patients achieved CR, nine patients CRu and four patients PR. The restaging procedures after consolidation radiotherapy showed an overall response rate of 95% (9 CR and 9 CRu). With a median follow-up of 56 months, progression free survival and overall survival at 60 months were 88%. The most common grade 3/4 hematological toxicities were leukocytopenia and neutropenia (100%), thrombocytopenia (95%), and anemia (63%). Conclusion: Our data suggest that the current high-dose methotrexate-based chemotherapy protocol followed by consolidation mediastinal radiotherapy in patients with adult PMLBCL is feasible, effective, and moderately tolerated.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded380    
    Comments [Add]    
    Cited by others 1    

Recommend this journal